By Kelly Cloonan
Shares of Dyne Therapeutics gained after the company shared positive data from a continuing trial of a potential Duchenne muscular dystrophy treatment.
The stock rose 14%, to $16.93, midday Monday. Shares have climbed 37% in the past year.
In the continuing Phase 1/2 trial, patients treated with zeleciment rostudirsen experienced improvement in heart and lung function through 24 months, compared with expected declines, the company said. The data builds on previous results that showed the treatment led to improvement across several measures including muscle function.
"Cardiopulmonary issues are a key area of concern in DMD, so we are particularly encouraged by new analyses," Chief Medical Officer Doug Kerr said.
The Waltham, Mass., company also said its starting a Phase 3 trial for a different treatment, zeleciment basivarsen, in individuals with myotonic dystrophy type 1.
The trial will enroll about 150 people and aims to assess the efficacy, safety and tolerability of the treatment administered intravenously. It is intended to support traditional approval of the treatment in the U.S. and to support marketing applications elsewhere, the company said.
Dyne said it has aligned with the Food and Drug Administration on the trial design and protocol.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 09, 2026 12:25 ET (16:25 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.